Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. Read more >>